Richard Belt, DO
Internal Medicine · Lexington, KYNPI 1275064263
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Pulmonx Corporation at 57.5% of the total. 2025 is the largest year on record at $9,224, 2.6 times the $3,580 reported in 2022. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $221.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$8K
- Intuitive Surgical$6K
- Boehringer Ingelheim$190
- Insmed, Inc.$89
- Inspire Medical Systems, Inc.$83
- AstraZeneca$67
- plus $185 from 7 others
What the payments were for
- Consulting fees$4,80033%
- Travel & lodging$7,32051%
- Food & beverage$2,25516%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 22 | $8,292 |
| Intuitive Surgical | 18 | $5,503 |
| Boehringer Ingelheim | 7 | $190 |
| Insmed, Inc. | 4 | $89 |
| Inspire Medical Systems, Inc. | 3 | $83 |
| AstraZeneca | 4 | $67 |
| Abiomed | 1 | $59 |
| Amgen | 1 | $34 |
| Harmony Biosciences LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| GSK | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$7,680
- Da Vinci Surgical System$5,335
- CHARTIS CATHETER$1,469
- ZEPHYR DELIVERY CATHETER$1,469
- PULMONX CHARTIS TABLET CONSOLE$1,469
How this compares
$14,409 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 34 | $128,640 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $54,343 |
| SymbicortBudesonide/Formoterol Fumarate | 148 | $39,846 |
| Spiriva HandihalerTiotropium Bromide | 36 | $28,656 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $27,711 |
| Spiriva RespimatTiotropium Bromide | 48 | $27,429 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $22,948 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $21,510 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $18,772 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $13,437 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $12,746 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $9,101 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $8,428 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $8,043 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $7,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $17 | $96,063160 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $67 | $69,784191 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $190 | $64,242102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Lexington
- David ManninoLexington$168K
- Fadi BachaLexington$31K
- Jad BalloutLexington$30K
- Thomas von UnrugLexington$22K
- Danilo CoralesLexington$17K
- Mohamed TashaniLexington$17K
- Kelli TrentLexington$16K
- Coutney SchniedersLexington$12K
- Fares KhaterWhitesburg$412K
- Bernard BuchananOwensboro$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.